Clot-busting drug for large brain bleeding
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a clot-busting medication (tenecteplase, or TNK) to see if it can safely break down the blood clot in your brain after a large bleed. If you are eligible, you may receive this treatment to help your body reabsorb the clot.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You had a large brain bleed (at least 30 mL) within the last 24 hours.
- Your blood pressure has been under 180 (systolic) for at least 6 hours.
- You were not on blood thinners (like warfarin, dabigatran, apixaban, or rivaroxaban) before the bleed.
- You had no significant disability before the bleed (were able to do daily activities independently).
- A CT scan shows the bleed is not growing, and you have not had brain surgery or certain other conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a clot-busting drug called tenecteplase given directly into the brain bleed through a thin tube. It may help reduce damage and improve recovery for people with a certain type of brain hemorrhage.
This trial looks at giving a clot-busting medicine directly into the brain arteries (intra-arterial TNK) when a stroke procedure (thrombectomy) doesn’t reopen the blocked vessel enough. It aims to improve recovery by improving blood flow while checking for safety, especially bleeding risk.
This trial tests whether giving IV TNK (tenecteplase) plus standard stroke care can improve outcomes in some people who have a new stroke but cannot get alteplase (another clot-busting drug) and do not have a large blocked artery that can be treated with a procedure. It’s meant for strokes with “mismatch” findings on scans that suggest salvageable brain tissue.
This trial tests a clot-busting drug (rhTNK-tPA) to remove blood from the ventricles (fluid spaces deep in the brain) after a spontaneous brain bleed. It may help patients whose ventricles are blocked by a large clot, reducing pressure and improving recovery.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
This trial tests a clot-busting drug called tenecteplase for people who had a stroke in the back of the brain and arrive at the hospital within 4.5 to 24 hours of symptoms. It aims to see if giving this drug later than usual can improve recovery and reduce disability.
Hear when a new Intracerebral Hemorrhage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.